Comparison of Incidence of Acute Myocardial Infarction in Patients With Type 2 Diabetes Mellitus Following Initiation of Neutral Protamine Hagedorn Insulin Versus Insulin Glargine

American Journal of Cardiology

Volumn 104, Issue 7, 2009, Pages 910-916

  Rhoads, George G ^a   Kosiborod, Mikhail ^b   Nesto, Richard W ^c   Fonseca, Vivian A ^d   Lu, Shou En ^a   Zhang, Quanwu ^e   Foody, Joanne M ^f  

^a University of Medicine and Dentistry   (United States)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^c LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^d TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e SANOFI   (France)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN GLARGINE; ISOPHANE INSULIN;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH INSURANCE; HUMAN; INCIDENCE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POISSON DISTRIBUTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGE DISTRIBUTION; CONFIDENCE INTERVALS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; INSULIN, NPH; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; POISSON DISTRIBUTION; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; STATISTICS, NONPARAMETRIC; UNITED STATES;

EID: 70249117868     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.05.030     Document Type: Article

References (30)

1. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
2. Lipscombe L.L., Gomes T., Levesque L.E., Hux J.E., Juurlink D.N., and Alter D.A. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298 (2007) 2634-2643
3. Lincoff A.M., Wolski K., Nicholls S.J., and Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007) 1180-1188
4. Diabetes: under-treated and widespread. Therapeutic Categories Outlook (2007), Cowen & Company 271-332
5. Janka H.U., Plewe G., Riddle M.C., Kliebe-Frisch C., Schweitzer M.A., and Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diab Care 28 (2005) 254-259
6. Riddle M.C. The treat-to-target trial and related studies. Endocr Pract 12 Suppl 1 (2006) 71-79
7. Yki-Jarvinen H., Kauppinen-Makelin R., Tiikkainen M., Vahatalo M., Virtamo H., Nikkila K., Tulokas T., Hulme S., Hardy K., McNulty S., Hanninen J., Levanen H., Lahdenpera S., Lehtonen R., and Ryysy L. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 49 (2006) 442-451
8. Ashwell S.G., Amiel S.A., Bilous R.W., Dashora U., Heller S.R., Hepburn D.A., Shutler S.D., Stephens J.W., and Home P.D. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabet Med 23 (2006) 285-292
9. Gough S.C. A review of human and analogue insulin trials. Diab Res Clin Pract 77 (2007) 1-15
10. Davis M.D., Beck R.W., Home P.D., Sandow J., and Ferris F.L. Early retinopathy progression in four randomized trials comparing insulin glargine and NPH insulin. Exp Clin Endocrinol Diab 115 (2007) 240-243
11. Horvath K., Jeitler K., Berghold A., Ebrahim S.H., Gratzer T.W., Plank J., Kaiser T., Pieber T.R., and Siebenhofer A. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev (2007) CD005613:1-73
12. Gomez-Caminero A., Blumentals W.A., Russo L.J., Brown R.R., and Castilla-Puentes R. Does panic disorder increase the risk of coronary heart disease?. A cohort study of a national managed care database. Psychosom Med 67 (2005) 688-691
13. Spyropoulos A. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 13 (2007) 475-486
14. Charlson M.E., Ales K.L., Simon R., and MacKenzie C.R. Why predictive indexes perform less well in validation studies: is it magic or methods?. Arch Intern Med 147 (1987) 2155-2161
15. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987) 373-383
16. Deyo R.A., Cherkin D.C., and Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45 (1992) 613-619
17. Miller D.R., Fincke B.G., and Christiansen C. Does insulin glargine use decrease cardiovascular disease risk?. Abstract presented at the 67th Annual Scientific Sessions American Diabetes Association, June 22-26, 2007; Chicago, IL. Abstract 2359-PO. Diabetes 56 suppl 1 (2007) A598
18. O'Sullivan J.B., and D'Agostino R.B. Decisive factors in the tolbutamide controversy. JAMA 232 (1975) 825-829
19. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
20. Singh S., Loke Y.K., and Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298 (2007) 1189-1195
21. Gerstein H.C., Miller M.E., Byington R.P., Goff Jr. D.C., Bigger J.T., Buse J.B., Cushman W.C., Genuth S., Ismail-Beigi F., Grimm Jr. R.H., Probstfield J.L., Simons-Morton D.G., and Friedewald W.T. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
22. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., Marre M., Cooper M., Glasziou P., Grobbee D., Hamet P., Harrap S., Heller S., Liu L., Mancia G., Mogensen C.E., Pan C., Poulter N., Rodgers A., and Williams B. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008) 2560-2572
23. Mullins P., Sharplin P., Yki-Jarvinen H., Riddle M.C., and Haring H.U. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 29 (2007) 1607-1619
24. Desouza C., Salazar H., Cheong B., Murgo J., and Fonseca V. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diab Care 26 (2003) 1485-1489
25. Bereket A., Lang C.H., Blethen S.L., Gelato M.C., Fan J., Frost R.A., and Wilson T.A. Effect of insulin on the insulin-like growth factor system in children with new-onset insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 80 (1995) 1312-1317
26. Juul A., Scheike T., Davidsen M., Gyllenborg J., and Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 106 (2002) 939-944
27. Twickler M.T., Cramer M.J., and Koppeschaar H.P. Unraveling Reaven's syndrome X: serum insulin-like growth factor-I and cardiovascular disease. Circulation 107 (2003) e190-e192
28. Ekstrom K., Salemyr J., Zachrisson I., Carlsson-Skwirut C., Ortqvist E., and Bang P. Normalization of the IGF-IGFBP axis by sustained nightly insulinization in type 1 diabetes. Diab Care 30 (2007) 1357-1363
29. Sukhanov S., Higashi Y., Shai S.Y., Vaughn C., Mohler J., Li Y., Song Y.H., Titterington J., and Delafontaine P. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 27 (2007) 2684-2690
30. Asleh R., Blum S., Kalet-Litman S., Alshiek J., Miller-Lotan R., Asaf R., Rock W., Aviram M., Milman U., Shapira C., Abassi Z., and Levy A.P. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes 57 (2008) 2794-2800